Welcome to the April 2026 issue of Regulatory Rapporteur which focuses on access to medicines.

Access is no longer a downstream consequence of regulatory approval; it has become the organising principle shaping how medicines are developed, evaluated and ultimately delivered to patients. The articles in our April issue show how lifecycle regulation, diverse evidence, operational innovation and cross-sector collaboration all contribute to improving the timely, equitable and trusted delivery of medicines.